Impact of a policy to permit the return of donors repeat-reactive to the Abbott PRISM antibody to hepatitis B core antigen assay

Transfusion

Volumn 49, Issue 2, 2009, Pages 271-277

  O'Brien, Sheila F ^a   Yi, Qi Long ^b   Fan, Wenli ^b   Fearon, Margaret A ^b   Scalia, Vito ^b   Goldman, Mindy ^b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; ATTITUDE TO HEALTH; BLOOD DONOR; CONTROLLED STUDY; DONOR SELECTION; FALSE POSITIVE RESULT; FEMALE; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOASSAY; INFECTION CONTROL; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; SCREENING;

AGE DISTRIBUTION; BLOOD DONORS; CANADA; CASE-CONTROL STUDIES; DNA, VIRAL; DONOR SELECTION; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LOGISTIC MODELS; MALE; PUBLIC POLICY; REGRESSION ANALYSIS;

EID: 58849138055     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01973.x     Document Type: Article

References (20)

1. Kiely P, Wood E. Can we improve the management of blood donors with non-specific reactivity in viral screening and confirmatory assays? Transfus Med Rev 2005 19 : 58 65.
2. U.S. Food and Drug Administration. Guidance for Industry. Nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry [PDF version]. Rockville (MD) : FDA 2005 cited 2008 May 15]. Available from: http://www.fda.gov/cber/gdlns/nathivhcv.htm
3. O'Brien SF, Fearon MA, Yi QL, Fan W, Scalia V, Muntz IR, Vamvakas EC. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion 2007 47 : 1809 15.
4. O'Brien SF, Xi G, Fan W, Yi QL, Fearon MA, Scalia V, Goldman M. Epidemiology of hepatitis B in Canadian blood donors. Transfusion 2008 Jul 11. [Epub ahead of print AM, Schmidt L, Krenc C, Pavlisjenkins L, Brady J, Taskar S, Angusfinn L, Mimms L. Improvements in detection of antibody to hepatitis B core antigen by treating specimens with reducing agent in an automated microparticle enzyme immunoassay. J Clin Microbiol 1991 29 : 611 6.
5. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003 43 : 696 704.
6. Stramer SL, Dodd RY. Donor reentry. In : Eder A, Bianco C, editors. Screening blood donors: science, reason and the donor history questionnaire. Bethesda (MD) : AABB Press 2007. p. 219 44.
7. Dawar M, Patrick DM, Bigham M, Cook D, Krajden M, Ng H. Impact of universal preadolescent vaccination against hepatitis B on antenatal seroprevalence of hepatitis B markers in British Columbia women. CMAJ 2003 18 : 703 4.
8. Comanor I, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006 91 : 1 12.
9. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the national health and nutrition examination surveys, 1976 through 1994. Am J Public Health 1999 89 : 14 8.
10. Kuhns MC, Busch MP. New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods. Mol Diagn Ther 2006 10 : 77 91.
11. Custer B, Johnson ES, Sullivan SD, Hazlet TK, Ramsey SD, Hirschler NV, Murphy EL, Busch MP. Quantifying losses to the donated blood supply due to donor deferral and mis-collection. Transfusion 2004 44 : 1417 26.
12. O'Brien SF, Ram SS, Vamvakas EC, Goldman M. The Canadian blood donor health assessment questionnaire: lessons from history, application of cognitive science principles, and recommendations for change. Transfusion Med Reviews 2007 21 : 205 22.
13. Riley W, Schwei M, McCullough J. The United States' potential blood donor pool: estimating the prevalence of donor-exclusion factors on the pool of potential donors. Transfusion 2007 47 : 584 90.
14. Custer B, Chinn A, Hirschler NV, Busch MP, Murphy EL. The consequences of temporary deferral on future whole blood donation. Transfusion 2007 47 : 1514 23.
15. France JL, France CR, Himawan LK. A path analysis of intention to redonate among experienced blood donors: an extension of the theory of planned behaviour. Transfusion 2007 47 : 1006 13.
16. Newman BH, Pichette S, Pichette D, Dzaka E. Adverse effects in blood donors after whole-blood donation: a study of 1000 blood donors interviewed 3 weeks after whole-blood donations. Transfusion 2003 43 : 598 603.
17. Piliavin JA, Callero PL. Giving blood: the development of an altruistic identity. Baltimore (MD) : Johns Hopkins University Press 1991.
18. Whittaker S, Carter N, Arnold E, Shehata N, Webert KE, DiStefano L, Heddle NM. Understanding the meaning of permanent deferral for blood donors. Transfusion 2008 48 : 64 72.
19. Kiely P, Stewart Y, Castro L. Analysis of voluntary blood donors with biologic false reactivity on chemiluminescent immunoassays and implications for donor management. Transfusion 2003 43 : 584 90.
20. Moore MC, Howell DR, Barbara JA. Donors whose blood reacts falsely positive in transfusion microbiology screening assays need not be lost to transfusion. Transfus Med 2007 17 : 55 9.